Andrew J Wilson1, Matthew Stubbs2, Phillip Liu2, Bruce Ruggeri2, Dineo Khabele3. 1. Department of Obstetrics & Gynecology, Vanderbilt University Medical Center, Nashville, TN, United States; Vanderbilt-Ingram Cancer Center, Nashville, TN, United States. 2. Incyte Corporation, Wilmington, DE, United States. 3. The University of Kansas Medical Center, Kansas City, KS, United States; The University of Kansas Cancer Center, Kansas City, KS, United States. Electronic address: dkhabele@kumc.edu.
Abstract
OBJECTIVE: Homologous recombination (HR)-proficient ovarian tumors have poorer clinical outcomes and show resistance to poly ADP ribose polymerase inhibitors (PARPi). A subset of HR-proficient ovarian tumors show amplification in bromodomain and extra-terminal (BET) genes such as BRD4. We aimed to test the hypothesis that BRD4 inhibition sensitizes ovarian cancer cells to PARPi by reducing HR efficiency and increasing DNA damage. METHODS: HR-proficient ovarian cancer cell lines (OVCAR-3, OVCAR-4, SKOV-3, UWB1.289+BRCA1) were treated with BRD4-targeting siRNA, novel (INB054329, INCB057643) and established (JQ1) BET inhibitors (BETi) and PARPi (olaparib, rucaparib). Cell growth and viability were assessed by sulforhodamine B assays in vitro, and in SKOV-3 and ovarian cancer patient-derived xenografts in vivo. DNA damage and repair (pH2AX, RAD51 and BRCA1 foci formation, and DRGFP HR reporter activity), apoptosis markers (cleaved PARP, cleaved caspase-3, Bax) and proliferation markers (PCNA, Ki67) were assessed by immunofluorescence and western blot. RESULTS: In cultured cells, inhibition of BRD4 by siRNA or INCB054329 reduced expression and function of BRCA1 and RAD51, reduced HR reporter activity, and sensitized the cells to olaparib-induced growth inhibition, DNA damage induction and apoptosis. Synergy was observed between all BETi tested and PARPi. INCB054329 and olaparib also co-operatively inhibited xenograft tumor growth, accompanied by reduced BRCA1 expression and proliferation, and increased apoptosis and DNA damage. CONCLUSIONS: These results provide strong rationale for using BETi to extend therapeutic efficacy of PARPi to HR-proficient ovarian tumors and could benefit a substantial number of women diagnosed with this devastating disease.
OBJECTIVE: Homologous recombination (HR)-proficient ovarian tumors have poorer clinical outcomes and show resistance to poly ADP ribose polymerase inhibitors (PARPi). A subset of HR-proficient ovarian tumors show amplification in bromodomain and extra-terminal (BET) genes such as BRD4. We aimed to test the hypothesis that BRD4 inhibition sensitizes ovarian cancer cells to PARPi by reducing HR efficiency and increasing DNA damage. METHODS:HR-proficient ovarian cancer cell lines (OVCAR-3, OVCAR-4, SKOV-3, UWB1.289+BRCA1) were treated with BRD4-targeting siRNA, novel (INB054329, INCB057643) and established (JQ1) BET inhibitors (BETi) and PARPi (olaparib, rucaparib). Cell growth and viability were assessed by sulforhodamine B assays in vitro, and in SKOV-3 and ovarian cancerpatient-derived xenografts in vivo. DNA damage and repair (pH2AX, RAD51 and BRCA1 foci formation, and DRGFP HR reporter activity), apoptosis markers (cleaved PARP, cleaved caspase-3, Bax) and proliferation markers (PCNA, Ki67) were assessed by immunofluorescence and western blot. RESULTS: In cultured cells, inhibition of BRD4 by siRNA or INCB054329 reduced expression and function of BRCA1 and RAD51, reduced HR reporter activity, and sensitized the cells to olaparib-induced growth inhibition, DNA damage induction and apoptosis. Synergy was observed between all BETi tested and PARPi. INCB054329 and olaparib also co-operatively inhibited xenograft tumor growth, accompanied by reduced BRCA1 expression and proliferation, and increased apoptosis and DNA damage. CONCLUSIONS: These results provide strong rationale for using BETi to extend therapeutic efficacy of PARPi to HR-proficient ovarian tumors and could benefit a substantial number of women diagnosed with this devastating disease.
Authors: Aiste McCormick; Peter Donoghue; Michelle Dixon; Richard O'Sullivan; Rachel L O'Donnell; James Murray; Angelika Kaufmann; Nicola J Curtin; Richard J Edmondson Journal: Clin Cancer Res Date: 2016-10-04 Impact factor: 12.531
Authors: Sergey Karakashev; Hengrui Zhu; Yuhki Yokoyama; Bo Zhao; Nail Fatkhutdinov; Andrew V Kossenkov; Andrew J Wilson; Fiona Simpkins; David Speicher; Dineo Khabele; Benjamin G Bitler; Rugang Zhang Journal: Cell Rep Date: 2017-12-19 Impact factor: 9.423
Authors: A Koff; A Giordano; D Desai; K Yamashita; J W Harper; S Elledge; T Nishimoto; D O Morgan; B R Franza; J M Roberts Journal: Science Date: 1992-09-18 Impact factor: 47.728
Authors: D C Schultz; L Vanderveer; K H Buetow; M P Boente; R F Ozols; T C Hamilton; A K Godwin Journal: Cancer Res Date: 1995-05-15 Impact factor: 12.701
Authors: Georgios Pongas; Marianne K Kim; Dong J Min; Carrie D House; Elizabeth Jordan; Natasha Caplen; Sirisha Chakka; Joyce Ohiri; Michael J Kruhlak; Christina M Annunziata Journal: Oncotarget Date: 2017-05-03
Authors: Shoumei Bai; Sarah E Taylor; Mohd Azrin Jamalruddin; Stacy McGonigal; Edward Grimley; Dongli Yang; Kara A Bernstein; Ronald J Buckanovich Journal: Mol Cancer Ther Date: 2022-09-06 Impact factor: 6.009
Authors: Patrick L Garcia; Aubrey L Miller; Ling Zeng; Robert C A M van Waardenburg; Eddy S Yang; Karina J Yoon Journal: Front Oncol Date: 2022-06-20 Impact factor: 5.738
Authors: Vijayalaxmi G Gupta; Jeff Hirst; Shariska Petersen; Katherine F Roby; Meghan Kusch; Helen Zhou; Makena L Clive; Andrea Jewell; Harsh B Pathak; Andrew K Godwin; Andrew J Wilson; Marta A Crispens; Emily Cybulla; Alessandro Vindigni; Katherine C Fuh; Dineo Khabele Journal: Gynecol Oncol Date: 2021-04-16 Impact factor: 5.304